abs83.txt	the	safety	and	efficacy	of	anticancer	antibody-drug	conjugates	(adcs)	depend	onthe	selection	tumor-targeting	monoclonal	antibody	(mab)		linker	drug	aswell	as	their	specific	chemical	arrangement	linkage	chemistry	in	this	study	we	used	a	heterobifunctional	cross-linker	to	conjugate	docetaxel	(dx)	tocetuximab	(cet)	or	panitumumab	(pan)	resulting	adcs	were	investigated	fortheir	vitro	egfr-specific	cytotoxicity	vivo	activity	reaction	conditions	such	reducing	agent	time	temperature	alkylationbuffer	optimized	yield	potent	stable	with	consistentbatch-to-batch	drug-to-antibody	ratios	(dars)	synthesized	darsfrom	0	4	3	all	retained	egfr	affinity	specificity	aftermodification	sensitive	cell	surface	wildtype	expression	demonstrating	more	egfr-expressing	a431	mda-mb-231	linescompared	u87mg	cells	tumor-bearing	mice	treated	once	weekly	for	fourweeks	100	mg/kg	cetuximab-docetaxel	adc	(c-sc-dx	dar	2	5)	showed	durableanticancer	responses	improved	overall	survival	compared	same	treatmentregimen	1	dx	cet	combination	mg/kgcet	new	treatment	options	are	emerging	patients	both	wild-type	andmutated	egfr-overexpressing	cancers	these	studies	highlight	potentialrole	egfr-targeted	therapies	promising	option
